Stage III Breast Cancer

HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer

TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

Improving Exercise Capacity With a Tailored Physical Activity Intervention

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer

Researching the Effect of Exercise on Cancer

A Study of Revaree Plus in People With Breast Cancer

Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET)

[18F]FES PET/CT for the Detection of Distant Metastasis in Low-grade ER-positive Stage III Breast Cancer

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

MARGetuximab Or Trastuzumab (MARGOT)

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer Survivors

Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment

A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.

SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)